(MedPage Today) — CHICAGO — A neoadjuvant chemotherapy regimen of cisplatin (Platinol), nab-paclitaxel (Abraxane), capecitabine (Xeloda), and gemcitabine (PAXG) topped a standard option in a randomized trial of resectable or borderline resectable…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115854
Author :
Publish date : 2025-06-02 16:57:00
Copyright for syndicated content belongs to the linked Source.
